Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Molecular Biomedicine is Scopus-indexed (Q1, CiteScore 11.7), WoS ESCI, DOAJ. Published by Springer International Publishing.
Checked against the index lists dated .
ISSN 2662-8651Verify ISSN ↗
Publisher: Springer International Publishing
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Molecular Medicine | 22 / 179 | 87th | Q1 |
| Molecular Biology | 53 / 414 | 87th | Q1 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2020–present, best quartile Q1, CiteScore 11.7.
Molecular Biomedicine is Q1 in Molecular Medicine (rank 22 of 179) and Q1 in Molecular Biology (rank 53 of 414), by CiteScore 2025.
Molecular Biomedicine is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 11.7, which places it in quartile Q1 at the 87th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 2.990, quartile Q1, with an H-index of 35.
The publisher lists an article processing charge of about US$2,590 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Molecular Biomedicine is published by Springer International Publishing. Its ISSN is 2662-8651.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
Molecular Biomedicine has an h-index of 54 and a 2-year mean of 11.16 citations per paper (OpenAlex). Its Scopus CiteScore is 11.7, quartile Q1. On 2-year citations it ranks #9 of 177 Scopus journals in Molecular Medicine.
Molecular Biomedicine published 153 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2026), authors are most often from China (69.8%), Spain (5%) and United States (4.7%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.